WallStreetZen

NYSE: PFE
Pfizer Inc Stock Forecast, Predictions & Price Target

Analyst price target for PFE

Based on 13 analysts offering 12 month price targets for Pfizer Inc.
Min Forecast
$36.00-1.91%
Avg Forecast
$41.92+14.23%
Max Forecast
$53.00+44.41%

Should I buy or sell PFE stock?

Buy
Strong Buy
5 analysts 33.33%
Buy
0 analysts 0%
Hold
10 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is PFE forecast to generate an efficient return?
Company
30.95%
Industry
74.22%
Market
62.25%
PFE's Return on Equity is forecast to be high in 4 years (30.95%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is PFE forecast to generate an efficient return on assets?
Company
11.29%
Industry
16.87%
Market
19.66%
PFE is forecast to generate lower Return on Assets (11.29%) than the US Drug Manufacturers - General industry average (16.87%)
Forecast

PFE earnings per share forecast

What is PFE's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$3.06+95.83%
Avg 2 year Forecast
$3.08+97.33%
Avg 3 year Forecast
$3.19+104.7%
PFE's earnings are forecast to grow at an exceptional rate of 26.97% per year
Forecast

PFE revenue forecast

What is PFE's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$55.3B+13.75%
Avg 2 year Forecast
$50.8B+4.52%
Avg 3 year Forecast
$50.3B+3.36%
PFE's revenue is forecast to grow at a rate of 1.11% per year, which is not exceptional
Forecast

PFE earnings growth forecast

How is PFE forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
26.97%
Industry
24.82%
Market
20.47%
PFE's earnings are forecast to grow faster (26.97% per year) than the US Drug Manufacturers - General industry average (24.82%)
Forecast
PFE's earnings are forecast to grow faster (26.97% per year) than the US market average (20.47%)
Forecast
PFE's earnings are forecast to grow faster (26.97% per year) than the risk-free savings rate (1.1%)
Forecast

PFE revenue growth forecast

How is PFE forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
1.11%
Industry
6.43%
Market
14.48%
PFE's revenues are forecast to grow slower (1.11% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
PFE's revenues are forecast to grow slower (1.11% per year) than the US market average (14.48%)
Forecast

Pfizer Stock Forecast FAQ

Is Pfizer Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NYSE: PFE) stock is to Buy PFE stock.

Out of 15 analysts, 5 (33.33%) are recommending PFE as a Strong Buy, 0 (0%) are recommending PFE as a Buy, 10 (66.67%) are recommending PFE as a Hold, 0 (0%) are recommending PFE as a Sell, and 0 (0%) are recommending PFE as a Strong Sell.

What is PFE's Price Target?

According to 13 Wall Street analysts that have issued a 1 year PFE price target, the average PFE price target is $41.92, with the highest PFE stock price forecast at $53.00 and the lowest PFE stock price forecast at $36.00.

On average, Wall Street analysts predict that Pfizer's share price could reach $41.92 by Jan 15, 2022. The average Pfizer stock price prediction forecasts a potential upside of 14.23% from the current PFE share price of $36.70.

What is PFE's earnings growth forecast for 2021-2023?

(NYSE: PFE) Pfizer's forecast annual earnings growth rate of 26.97% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 24.82%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 20.47%.

Pfizer's earnings in 2020 is $8,685,000,000.On average, 2 Wall Street analysts forecast PFE's earnings for 2021 to be $16,976,267,810, with the lowest PFE earnings forecast at $16,670,639,421, and the highest PFE earnings forecast at $17,281,896,200. On average, 6 Wall Street analysts forecast PFE's earnings for 2022 to be $17,105,743,110, with the lowest PFE earnings forecast at $15,170,281,873, and the highest PFE earnings forecast at $18,170,996,969.

In 2023, PFE is forecast to generate $17,744,784,288 in earnings, with the lowest earnings forecast at $15,670,401,056 and the highest earnings forecast at $19,115,666,536.

What is PFE's revenue growth forecast for 2021-2023?

(NYSE: PFE) Pfizer's forecast annual revenue growth rate of 1.11% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.

Pfizer's revenue in 2020 is $48,648,000,000.On average, 6 Wall Street analysts forecast PFE's revenue for 2021 to be $307,514,205,457,582, with the lowest PFE revenue forecast at $263,073,803,822,994, and the highest PFE revenue forecast at $348,111,791,316,678. On average, 6 Wall Street analysts forecast PFE's revenue for 2022 to be $282,551,462,180,341, with the lowest PFE revenue forecast at $267,146,996,721,525, and the highest PFE revenue forecast at $311,505,678,881,672.

In 2023, PFE is forecast to generate $279,404,389,984,205 in revenue, with the lowest revenue forecast at $267,719,355,341,646 and the highest revenue forecast at $307,054,173,605,880.

What is PFE's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: PFE) Pfizer's current Earnings Per Share (EPS) is $1.56. On average, analysts forecast that PFE's EPS will be $3.06 for 2021, with the lowest EPS forecast at $3.00, and the highest EPS forecast at $3.11. On average, analysts forecast that PFE's EPS will be $3.08 for 2022, with the lowest EPS forecast at $2.73, and the highest EPS forecast at $3.27. In 2023, PFE's EPS is forecast to hit $3.19 (min: $2.82, max: $3.44).

What is PFE's forecast return on equity (ROE) for 2021-2024?

(NYSE: PFE) forecast ROE is 30.95%, which is considered strong.

What is PFE's forecast return on assets (ROA) for 2021-2024?

(NYSE: PFE) forecast ROA is 11.29%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.87%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics